Therapy Areas: Inflammatory Diseases
TME Pharma announces extension of financial visibility to May 2026
21 May 2025 - Biotechnology company TME Pharma N.V. (Euronext Growth Paris: ALTME) announced on Wednesday that it has secured EUR1.7m in proceeds from a new bond issuance, extending its financial runw...
Nordic Bioscience launches new Endotrophin assay
19 May 2025 - Danish biomarker company Nordic Bioscience announced on Friday nordicEndotrophin, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin ...
InnoCare reports first patient dosed in Phase II/III vitiligo trial
16 May 2025 - Biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) reported on Friday that the first patient has been dosed in a Phase II/III clinical trial of Soficitinib (ICP-332) for...
AB Science reports masitinib shows neuroprotective potential in preclinical model of neurodegeneration
15 May 2025 - French pharmaceutical company AB Science SA (Euronext Paris:AB) on Thursday announced new findings published in PLOS One supporting the neuroprotective effects of masitinib in a preclini...
Formosa Pharmaceuticals and Apotex sign Mexico licensing agreement for clobetasol propionate ophthalmic suspension
7 May 2025 - Taiwan-based Formosa Pharmaceuticals (TW:6838) announced on Tuesday that the company has entered into an exclusive licensing agreement with Apotex Inc, a Canadian pharmaceutical company, ...
Innovent reports first patient dosed in efdamrofusp alfa (IBI302) Phase 2 study in diabetic macular edema
7 May 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Tuesday the completion of first patient dosing in the Phase 2 clinical study of efdamrofusp alfa (R&...